Efficacy and safety of OBI1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

R Kruse‐Jarres, J St‐Louis, A Greist, A Shapiro… - …, 2015 - Wiley Online Library
OBI-1 treatment 24 h after initiation despite inhibition of FVIII activity levels immediately after
infusion in 10 subjects with baseline anti-porcine … The results of this study indicate that OBI-1

[PDF][PDF] OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII

V Toschi - Curr Opin Mol Ther, 2010 - researchgate.net
OBI-1 is a bioengineered form of porcine rFVIII that is highly purified. OBI-1 has the
procoagulant and biochemical properties of porcine pdFVIII, with improvements in risk of toxicity, …

[HTML][HTML] Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A …

R Kruse-Jarres, JS Louis, A Greist, AD Shapiro… - Blood, 2013 - Elsevier
… the efficacy and safety of OBI-1 in the treatment of … OBI-1 (200 U/kg), followed by additional
doses based on the subject's target factor VIII levels, anti-OBI-1 titer, and clinical factors

[HTML][HTML] Recombinant Porcine Factor VIII Corrects Thrombin Generation and Improves Clot Structure In Vitro in Plasma Containing Anti-Factor VIII Inhibitory Antibodies

C Negrier, SL Meeks, J Oldenburg, U Martinowitz… - Blood, 2011 - Elsevier
… thrombin generation with even the highest dose of OBI-1 all had antibody detected to
more than one domain of FVIII or were not able to be mapped due to high porcine cross-reactivity. …

[HTML][HTML] Recombinant porcine factor VIII, Obi-1, successfully controlled gastrointestinal bleeding in a patient with acquired hemophilia A

MK Riaz, S Girnius, JE Palascak - Blood, 2015 - Elsevier
… The recombinant porcine FVIII (rpFVIII), OBI-1, recently obtained … AHA admitted with a GIB
and successfully treated with OBI-1. … FVIII level was <1% with factor VIII inhibitor titer of 245 …

[HTML][HTML] A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A …

J Mahlangu, TA Andreeva, D Macfarlane, MT Reding… - Blood, 2007 - Elsevier
… The results suggest that a LD is not needed with OBI-1 treatment, and in some instances …
dose range for OBI-1 and to confirm the long term safety and efficacy of OBI-1 in the treatment of …

Porcine recombinant factor VIII (Obizur; OBI1; BAX 801): product characteristics and preclinical profile

D Lillicrap, A Schiviz, C Apostol, P Wojciechowski… - …, 2016 - Wiley Online Library
… with human plasma factors (eg thrombin and factor IXa) to develop its procoagulant activity.
… Consequently, OBI-1 is synthesized as a 1448 amino acid single-chain polypeptide (Fig. 1) …

Pharmacokinetics and safety of OBI1, a recombinant B domain‐deleted porcine factor VIII, in subjects with haemophilia A

CL Kempton, TC Abshire, RA Deveras, WK Hoots… - …, 2012 - Wiley Online Library
… of recombinant porcine FVIII, OBI-1, in humans. Results from this study suggest that OBI-1 is
… but without significant anti-porcine FVIII inhibitors (Hyate:C or OBI-1), and it is well tolerated. …

[HTML][HTML] Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies

PM Mannucci, M Franchini - Blood Transfusion, 2017 - ncbi.nlm.nih.gov
… Obizur (OBI-1) is a high-purity B-domain deleted form of porcine FVIII produced by recombinant
DNA technology in baby hamster kidney cells grown in a serum-free medium. It has the …

[HTML][HTML] Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate: C in hemophilia A mice presensitized to human factor VIII

ET Parker, HN Craddock, RT Barrow, P Lollar - Journal of Thrombosis and …, 2004 - Elsevier
… -derived porcine factor (F)VIII concentrate that is used in the treatment of patients with
inhibitory antibodies to FVIII. OBI-1 is a recombinant B domain-deleted form of porcine FVIII that is …